oxybutynin has been researched along with Contact Dermatitis in 9 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 6.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 2.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| " The most common adverse event for OXY-TDS was localized application site pruritus (14% versus 4% placebo) accompanied by a low incidence of systemic side effects (eg, dry mouth 4." | 2.71 | Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. ( Davila, GW; Dmochowski, RR; Gittelman, MC; Sand, PK; Sanders, SW; Zinner, NR, 2003) |
| " Rivastigmine, a cholinesterase inhibitor, is commonly used as a treatment for dementia due to its ability to moderate cholinergic neurotransmission; however, treatment with oral rivastigmine can lead to gastrointestinal adverse effects such as nausea and vomiting." | 2.47 | Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. ( Adam, DN; Greenspoon, J; Herrmann, N, 2011) |
| "Safety and tolerability assessment included the monitoring and recording of adverse events and withdrawals at any time during the study." | 1.38 | Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions. ( Pregelj, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Dmochowski, RR | 1 |
| Sand, PK | 1 |
| Zinner, NR | 1 |
| Gittelman, MC | 1 |
| Davila, GW | 1 |
| Sanders, SW | 1 |
| Khoo, ABS | 1 |
| Haque-Hussain, S | 1 |
| Kaunitz, AM | 1 |
| Portman, D | 1 |
| Westhoff, CL | 1 |
| Mishell, DR | 1 |
| Archer, DF | 1 |
| Foegh, M | 1 |
| Yataba, I | 1 |
| Otsuka, N | 1 |
| Matsushita, I | 1 |
| Matsumoto, H | 1 |
| Hoshino, Y | 1 |
| Greenspoon, J | 1 |
| Herrmann, N | 1 |
| Adam, DN | 1 |
| Pregelj, P | 1 |
| KLAUDER, JV | 1 |
| MORRIS, GE | 1 |
| BIRMINGHAM, DJ | 1 |
| FLEGEL, H | 1 |
| FIEDLER, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.[NCT01181479] | Phase 3 | 1,504 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measuring the breakthrough bleeding (BTB) and/or breakthrough spotting (BTS). Measured as a percent of total number of cycles in each Arm/Group with BTB and/or BTS. (NCT01181479)
Timeframe: 6 months
| Intervention | percentage of cycles with BTB/BTS (Number) |
|---|---|
| AG200-15 for Cycle 1-6 | 23.9 |
| Lessina | 21.2 |
"Evaluation of patch adhesion was determined using the following scores:~0: >= 90% adhered (no lift)~>= 75% adhered but < 90% (some edges showing lift)~>= 50% adhered but < 75% (half of system lifts off)~< 50% (> half of system lifts off, but undetached)~patch completely detached" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 0.29 |
Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use. (NCT01181479)
Timeframe: AG200-15: 6 months; Lessina: 6 months; AG200-15: 1 year
| Intervention | Pearl Index (Number) |
|---|---|
| AG200-15 for Cycle 7-13 | 5.41 |
| Lessina | 6.67 |
| AG200-15 for Cycle 1-13 | 6.43 |
"Evaluation of irritation at application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.35 |
"Evaluation of itching at patch application site was determined using the following scores:~0: None~Mild~Moderate~Severe" (NCT01181479)
Timeframe: 1 year
| Intervention | Score on a scale (Mean) |
|---|---|
| All Subjects Who Applied AG200-15 | 1.48 |
Measurement of plasma concentrations of LNG and EE for cycles 2, 6 and 13. (NCT01181479)
Timeframe: Lessina: 6 months; AG200-15: 1 year; AG200-15: 6 months
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| EE for cycle 2 | EE cycle 6 | EE cycle 13 | LNG cycle 2 | LNG cycle 6 | LNG cycle 13 | |
| AG200-15 for Cycle 1-13 | 30.5 | 36.7 | 31 | 1201 | 1753 | 1590 |
| AG200-15 for Cycles 7-13 | NA | NA | 33.4 | NA | NA | 1750 |
| Lessina Cycles 1-6 | 35.4 | 40.1 | NA | 2386 | 2611 | NA |
1 review available for oxybutynin and Contact Dermatitis
| Article | Year |
|---|---|
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Allergic Contac | 2011 |
3 trials available for oxybutynin and Contact Dermatitis
| Article | Year |
|---|---|
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Cresols; Dermatitis, Contact; | 2003 |
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
Topics: Adhesiveness; Adolescent; Adult; Contraceptives, Oral, Combined; Dermatitis, Contact; Drug Combinati | 2015 |
The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Contact; Female; | 2016 |
5 other studies available for oxybutynin and Contact Dermatitis
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
A differential diagnosis for annular lesions: contact dermatitis to transdermal rivastigmine patches.
Topics: Aged; Dermatitis, Contact; Diagnosis, Differential; Humans; Male; Memory Disorders; Neuroprotective | 2018 |
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibit | 2012 |
Dermatology in industrial medicine. II. Of what value is pre-employment patch test?
Topics: Dermatitis; Dermatitis, Contact; Dermatology; Employment; Humans; Occupational Health; Occupational | 1957 |
[Studies on the diagnostic value of the epicutaneous patch test].
Topics: Dermatitis, Contact; Humans; Occupational Diseases; Patch Tests; Skin Tests; Transdermal Patch | 1961 |